FDA Cites Gleevec For Promoting Unapproved Indications Three Weeks Before Expanding Label

Notice of violation letter to Novartis from FDA’s Office of Prescription Drug Promotion expresses concern about describing a patient with five-year survival data, a claim that was added to the label the following month.